Vonoprazan (Fumarate)

Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+, K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease[1][2].

Product Specifications

CAS Number

[881681-01-2]

Product Name Alternative

TAK-438

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Proton Pump

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/TAK-438.html

Purity

99.94

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)/C=C/C(O)=O.O=S(N1C=C(CNC)C=C1C2=CC=CC=C2F)(C3=CC=CN=C3)=O

Molecular Formula

C21H20FN3O6S

Molecular Weight

461.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB) . J Med Chem, 2012, 55 (9), 4446-4456.|[2]Hori Y, et al. 1-[5- (2-Fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335 (1), 231-238.